CB2 expression in human acute myeloid leukemia cells and normal myeloid precursors. (A) Flow cytometric analysis of a representative CB2-positive and a CB2-negative myeloid cell line. Staining was performed using a CB2 N-terminal antibody followed by FITC-conjugated secondary rabbit antibody. (B) CB2 cell surface expression analysis on primary AML patient samples and normal CD34⁺ bone marrow cells using the CB2 N-terminal antibody. (C) Immunophenotyping of normal total bone marrow using flow cytometric analysis.